526 related articles for article (PubMed ID: 25475434)
21. [Changes of podocyte ultrastructure and expression of podocyte-associated molecules in rats with diabetic nephropathy].
Chen LP; Zhou QL; Peng WS; Wu XY
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):620-5. PubMed ID: 17767053
[TBL] [Abstract][Full Text] [Related]
22. GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity.
Lu J; Chen PP; Zhang JX; Li XQ; Wang GH; Yuan BY; Huang SJ; Liu XQ; Jiang TT; Wang MY; Liu WT; Ruan XZ; Liu BC; Ma KL
Theranostics; 2021; 11(10):4728-4742. PubMed ID: 33754024
[No Abstract] [Full Text] [Related]
23. Lack of {alpha}8-integrin aggravates podocyte injury in experimental diabetic nephropathy.
Hartner A; Cordasic N; Menendez-Castro C; Volkert G; Yabu JM; Kupraszewicz-Hutzler M; Rascher W; Hilgers KF
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1151-7. PubMed ID: 20826576
[TBL] [Abstract][Full Text] [Related]
24. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
[TBL] [Abstract][Full Text] [Related]
25. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
Wang S; Li Y; Zhao J; Zhang J; Huang Y
Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
[TBL] [Abstract][Full Text] [Related]
26. Podocyte Shape Regulation by Semaphorin 3A and MICAL-1.
Tufro A
Methods Mol Biol; 2017; 1493():393-399. PubMed ID: 27787866
[TBL] [Abstract][Full Text] [Related]
27. Semaphorin3a disrupts podocyte foot processes causing acute proteinuria.
Tapia R; Guan F; Gershin I; Teichman J; Villegas G; Tufro A
Kidney Int; 2008 Mar; 73(6):733-40. PubMed ID: 18075495
[TBL] [Abstract][Full Text] [Related]
28. Depletion of Gprc5a Promotes Development of Diabetic Nephropathy.
Ma X; Schwarz A; Sevilla SZ; Levin A; Hultenby K; Wernerson A; Lal M; Patrakka J
J Am Soc Nephrol; 2018 Jun; 29(6):1679-1689. PubMed ID: 29636387
[No Abstract] [Full Text] [Related]
29. Differential expression of parietal epithelial cell and podocyte extracellular matrix proteins in focal segmental glomerulosclerosis and diabetic nephropathy.
Chan GC; Eng DG; Miner JH; Alpers CE; Hudkins K; Chang A; Pippin JW; Shankland SJ
Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1680-F1694. PubMed ID: 31630546
[TBL] [Abstract][Full Text] [Related]
30. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes.
Dong D; Fan TT; Ji YS; Yu JY; Wu S; Zhang L
Int Urol Nephrol; 2019 Apr; 51(4):755-764. PubMed ID: 30734886
[TBL] [Abstract][Full Text] [Related]
31. NOD2 promotes renal injury by exacerbating inflammation and podocyte insulin resistance in diabetic nephropathy.
Du P; Fan B; Han H; Zhen J; Shang J; Wang X; Li X; Shi W; Tang W; Bao C; Wang Z; Zhang Y; Zhang B; Wei X; Yi F
Kidney Int; 2013 Aug; 84(2):265-76. PubMed ID: 23594678
[TBL] [Abstract][Full Text] [Related]
32. Hyperoside reduces albuminuria in diabetic nephropathy at the early stage through ameliorating renal damage and podocyte injury.
Zhang J; Fu H; Xu Y; Niu Y; An X
J Nat Med; 2016 Oct; 70(4):740-8. PubMed ID: 27255369
[TBL] [Abstract][Full Text] [Related]
33. RhoA protects the podocytes against high glucose-induced apoptosis through YAP and plays critical role in diabetic nephropathy.
Huang Z; Peng Y; Yu H; Yu X; Zhou J; Xiao J
Biochem Biophys Res Commun; 2018 Oct; 504(4):949-956. PubMed ID: 30220545
[TBL] [Abstract][Full Text] [Related]
34. Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis.
Lenoir O; Jasiek M; Hénique C; Guyonnet L; Hartleben B; Bork T; Chipont A; Flosseau K; Bensaada I; Schmitt A; Massé JM; Souyri M; Huber TB; Tharaux PL
Autophagy; 2015; 11(7):1130-45. PubMed ID: 26039325
[TBL] [Abstract][Full Text] [Related]
35. Podocyte-specific deletion of Rac1 leads to aggravation of renal injury in STZ-induced diabetic mice.
Ishizaka M; Gohda T; Takagi M; Omote K; Sonoda Y; Oliva Trejo JA; Asao R; Hidaka T; Asanuma K; Horikoshi S; Tomino Y
Biochem Biophys Res Commun; 2015 Nov; 467(3):549-55. PubMed ID: 26435502
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker.
Su J; Li SJ; Chen ZH; Zeng CH; Zhou H; Li LS; Liu ZH
Diabetes Res Clin Pract; 2010 Feb; 87(2):167-75. PubMed ID: 19969384
[TBL] [Abstract][Full Text] [Related]
37. Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy.
Zhang Y; Ma KL; Liu J; Wu Y; Hu ZB; Liu L; Liu BC
Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1140-8. PubMed ID: 25921580
[TBL] [Abstract][Full Text] [Related]
38. Coro2b, a podocyte protein downregulated in human diabetic nephropathy, is involved in the development of protamine sulphate-induced foot process effacement.
Schwarz A; Möller-Hackbarth K; Ebarasi L; Unnersjö Jess D; Zambrano S; Blom H; Wernerson A; Lal M; Patrakka J
Sci Rep; 2019 Jun; 9(1):8888. PubMed ID: 31221975
[TBL] [Abstract][Full Text] [Related]
39. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
Zhang M; Liu M; Xiong M; Gong J; Tan X
J Ethnopharmacol; 2012 May; 141(1):111-8. PubMed ID: 22353431
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy.
Zhou Z; Wan J; Hou X; Geng J; Li X; Bai X
Cell Death Dis; 2017 Mar; 8(3):e2658. PubMed ID: 28277542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
